Business Wire

TX-MARY-KAY-INC

3.4.2024 20:13:34 CEST | Business Wire | Press release

Share
Mary Kay Inc. Spearheads Ocean Conservation Efforts at the 11th Annual World Ocean Summit

Mary Kay Inc., a global leader in women’s empowerment and staunch advocate for sustainability, is once again at the forefront of global ocean conservation efforts. The beauty brand was proud to participate at the 11th Annual World Ocean Summit & Expo, held in Lisbon, Portugal, from March 11-13. As a bronze level sponsor for the second consecutive year, Mary Kay demonstrated its unwavering commitment to fostering a sustainable blue economy as a private sector representative and through its long-standing collaboration with The Nature Conservancy (TNC).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240403166440/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Sandra Silva, General Manager of Mary Kay in Portugal, shared insights on the crucial need for collaborative efforts in marine conservation and highlighted the impact of incorporating gender perspectives in initiatives tackling climate change challenges and biodiversity loss. (Photo: Mary Kay Inc.)

The Annual World Ocean Summit & Expo, organized by Economist Impact, convened over 200 expert speakers and a diverse international audience to engage in meaningful discussions, workshops, and "How to" sessions. These gatherings focused on actionable solutions to some of the most pressing oceanic challenges, underlining the importance of collaborative efforts across sectors.

Sandra Silva, General Manager of Mary Kay Portugal, took an active role in the panel discussion titled "Developing Blue Nature-based Projects." Silva shared insights on the crucial need for collaborative efforts in marine conservation and highlighted the impact of incorporating gender perspectives in initiatives tackling climate change challenges and biodiversity loss.

"Mary Kay's participation at this year's World Ocean Summit was not only about reinforcing our dedication to ocean conservation, but also about spotlighting the essential role of women in these efforts,” said Silva. “We believe that our collective actions today are pivotal for the preservation of marine ecosystems. All stakeholders left the summit with a clear vision on new synergies, a focus on actionable strategies, and soundproof solutions to enhance ocean stewardship.”

Dr. Lizzie Mcleod, Global Ocean Director for The Nature Conservancy, expressed gratitude for their long-term and impactful relationship with Mary Kay. "Our strong collaboration stands as a testament to the power of joining forces across the scientific community and the private sector to improve ocean health. Mary Kay’s support of marine conservation initiatives, including the Super Reefs project in Palau, is one example of our collective effort to ensure a healthy and resilient ocean."

Mary Kay has been working to elevate ocean health and coral reef awareness through its support of The Nature Conservancy for 37 years. Some of the most recent projects include the Super Reef restoration in the Asia Pacific region and other projects in Hawaii, Palau, the Marshall Islands, and Belize. These projects align with Mary Kay's mission to not only enrich lives but also to ensure the longevity and health of marine environments for future generations.

DID YOU KNOW?

  • Mary Kay began supporting The Nature Conservancy (TNC) in 1987 and has now contributed to projects for more than three decades across 100 conservation projects around the globe.
  • As part of its mission to conserve the Earth’s land and water, TNC aims to conserve 4 billion hectares of ocean by 2030—including coral reefs.
  • Out of more than 1,500 articles published on coral reef sciences in OECD countries, 33% of authors were women.1
  • 13-24% of senior positions in the EU’s marine sciences sector are occupied by women.1
  • 90% of women in fisheries and aquaculture are more involved in less well-paid or unpaid work.1

About Mary Kay

Then. Now. Always. One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 35 countries. For 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on X (formerly Twitter).

About The Nature Conservancy

The Nature Conservancy is a global conservation organization dedicated to conserving the lands and waters on which all life depends. Guided by science, we create innovative, on-the-ground solutions to our world’s toughest challenges so that nature and people can thrive together. We are tackling climate change, conserving lands, waters, and oceans at an unprecedented scale, providing food and water sustainably, and helping make cities more sustainable. Working in 76 countries and territories —37 by direct conservation impact and 39 through partners— we use a collaborative approach that engages local communities, governments, the private sector, and other partners. To learn more, visit www.nature.org or follow @nature_press on Twitter.

1 Source : https://impact.economist.com/ocean/sustainable-ocean-economy/valuing-women-in-the-blue-economy-for-international-womens-day

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240403166440/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye